ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Outcomes of IVIG Monotherapy for Donor-Specific Antibodies After Lung Transplantation

K. Spence, S. Heeney, M. Morrison, S. A. Rega, F. D. Irene, K. B. Harrison, C. M. Shaver

Vanderbilt University Medical Center, Nashville, TN

Meeting: 2021 American Transplant Congress

Abstract number: 195

Keywords: Antibodies, Immunoglobulins (Ig), IVIG, Lung transplantation

Topic: Clinical Science » Lung » Lung: All Topics

Session Information

Session Name: When Opportunity Knocks... Identifying Interventions to Optimize Lung Transplant Outcomes

Session Type: Rapid Fire Oral Abstract

Date: Sunday, June 6, 2021

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:30pm-6:35pm

Location: Virtual

*Purpose: De novo donor-specific antibodies (DSA) are a risk factor for antibody mediated rejection (AMR) and poor clinical outcomes after lung transplant (LT). Intravenous immune globulin (IVIG) neutralizes circulating DSA and is thought to disrupt AMR. We tested the hypothesis that IVIG therapy is associated with reduced DSA intensity and increased FEV1 compared to observation alone.

*Methods: LT recipients from 2009 to 2019 with de novo DSA with mean fluorescence intensity (MFI) >3000 were included in this retrospective, single-center, observational analysis. Subjects were excluded if they had treatment in addition to IVIG, had a positive crossmatch, had IVIG prior to DSA, or had no follow-up DSA in 28-100 days. Subjects received IVIG only (n=23) or did not receive treatment (n=16). The trajectories of DSA MFI and FEV1 between the index and follow-up DSA were each tested via repeated measures analysis of variance with time by treatment group interaction effects. Additional outcomes were chronic lung allograft dysfunction and survival. Between-group comparisons were made using parametric and non-parametric tests and Kaplan Meier survival methods.

*Results: The study cohort included 39 LT patients (mean age 53±13y, 59% male, 80% double LT) with most having IPF (41%) or COPD (36%). The majority (85%) of DSAs targeted class II antigens. These baseline characteristics and the median interval between index and follow-up testing did not differ between groups (all p>0.203). While overall DSA MFI decreased over time (p=0.003), there was no significant difference in the trajectory of MFI between treatment groups (Panel A, p=0.789). In contrast, the trajectory of FEV1 increased over time in the IVIG group, but not in the no treatment group (Panel B, time by treatment interaction p=0.003). Mean FEV1 at DSA detection was 2.04±0.72 and 2.49±0.77 for the IVIG and no treatment groups, respectively (p=0.087). There was no between-group difference in CLAD (22% vs. 38%, p=0.307) or patient survival (log rank p=0.396).

 border=

*Conclusions: Although patients treated with IVIG alone for de novo DSA after LT have similar DSA MFI trajectories over time, their FEV1 increased after therapy. This result may be due to the trend towards lower FEV1 in the IVIG group at the time of DSA detection. Future studies are needed to determine the mechanisms by which IVIG affects FEV1 in the setting of DSA.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Spence K, Heeney S, Morrison M, Rega SA, Irene FD, Harrison KB, Shaver CM. Outcomes of IVIG Monotherapy for Donor-Specific Antibodies After Lung Transplantation [abstract]. Am J Transplant. 2021; 21 (suppl 3). https://atcmeetingabstracts.com/abstract/outcomes-of-ivig-monotherapy-for-donor-specific-antibodies-after-lung-transplantation/. Accessed May 9, 2025.

« Back to 2021 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences